Novo Nordisk Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Novo Nordisk Bundle
Visual. Strategic. Downloadable.
Novo Nordisk's BCG Matrix preview shows where its key products sit—but the real clarity comes with the full report. Buy the complete BCG Matrix to see quadrant-by-quadrant placements, data-driven recommendations, and which brands are true Stars or costly Dogs. Get instant access to a polished Word report plus an Excel summary you can present or act on immediately. Purchase now and turn this snapshot into a strategic roadmap for smarter capital and product decisions.
Stars
Wegovy (semaglutide) — obesity
Runaway demand and massive media attention, plus robust outcomes from the 2.4 mg weekly Wegovy (US approval 2021), put it at the star quadrant of a fast-growing obesity market projected to exceed $100 billion by 2030. It consumes heavy capex and commercial spend to expand capacity, launches, and access, yet revenue growth and margin expansion are matching the burn. Keep throttle to lock share while competitors scale; if growth normalizes it can convert into a dominant cash cow.
Ozempic (semaglutide) — T2D
Market-leading GLP‑1 for T2D, Ozempic (semaglutide) drives massive prescription momentum and strong payer and physician preference; Novo Nordisk reported Ozempic brought in >$10bn in revenue in 2024 and leads category share. Tailwinds from weight-loss and cardiovascular benefits expand indications, but sustained investment in supply, HCP education and label expansion is required. Hold share now and it will generate significant cash for a decade.
Rybelsus (oral semaglutide)
First-to-market oral GLP‑1 approved in 2019, Rybelsus gives Novo a unique wedge with needle-averse patients and broadens addressable market.
Growth runway remains long as awareness and access deepen globally, especially across primary care channels and emerging markets.
Still needs push on adherence, real‑world persistence and clearer payer positioning to translate prescriptions into sustained revenue.
With scale inside Novo’s GLP‑1 franchise, Rybelsus can become a durable profit engine.
Global GLP‑1 leadership (platform + capacity)
Global GLP‑1 leadership is defined less by single products and more by an end-to-end engine — manufacturing scale, API security and device innovation that soak capital yet create a durable moat; by 2024 this platform has enabled faster label and geographic rollouts, multiplying the value of each incremental indication.
- Platform moat: scale across API, manufacturing, devices
- Capital intensity: large capex protects share
- Multiplicative growth: every new label/geography leverages same engine
- Flywheel: R&D → approvals → scale → reinvestment
Cardio-metabolic outcomes franchise (label expansions)
Compelling outcomes data for GLP-1/GIP therapies broaden use beyond glucose and weight: STEP trials showed up to 15% mean weight loss, typical HbA1c reductions are 1.0–1.5%, and cardiovascular trials (REWIND, SELECT) demonstrated roughly 12–20% relative MACE risk reductions, each new claim raising the clinical ceiling and strengthening payer value.
- Label expansion impact: higher ceiling on eligible population
- Payer dynamics: stronger coverage leverage with CV and renal claims
- Barriers: promotion and RWE generation remain resource‑intensive
- Upside: nailing access compounds category leadership
GLP‑1 surge: obesity market >$100bn 2030; Ozempic >$10bn 2024
Novo’s GLP‑1s sit as Stars: Wegovy/Ozempic drove runaway demand (obesity market >$100bn by 2030) and Ozempic exceeded $10bn revenue in 2024, funding capex for scale and launches while margins expand. Rybelsus widens the base for needle-averse patients; platform scale (API, manufacturing, devices) multiplies returns but requires heavy spend to defend share.
| Product | 2024 rev | Key metric |
|---|---|---|
| Ozempic | >$10bn | Market leader |
| Wegovy | — | High demand, obesity upside |
| Rybelsus | — | Oral wedge |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Novo Nordisk products, showing Stars, Cash Cows, Question Marks, Dogs and strategic moves.
Customizable Excel Spreadsheet
One-page Novo Nordisk BCG Matrix locating units by growth/share to surface pain points and guide quick strategy fixes
Cash Cows
Insulin analogs (Tresiba, NovoRapid/Novolog, Fiasp)
Insulin analogs (Tresiba, NovoRapid/Novolog, Fiasp) are a mature category for Novo Nordisk with a dominant market presence and reliable volumes in 2024. Pricing pressure is real, but global scale and manufacturing efficiency keep margins healthy. Low promotional needs and steady cash conversion make them dependable cash cows. Continue milking while optimizing product mix and production footprint.
Victoza (liraglutide) — legacy GLP‑1
Victoza (liraglutide) remains a cash cow for Novo Nordisk in 2024, still generating multi-billion DKK annual sales and delivering steady margins despite patent tail effects in several markets. Low growth and limited incremental investment characterize its positioning, making profitability predictable and cash flow harvestable. It functions as a bridge product where newer GLP-1s lack access or reimbursement, so Novo should manage decline gracefully and maximize free cash extraction.
Norditropin — growth hormone
Norditropin is an established growth-hormone brand within Novo Nordisk with high market share in pediatric and adult GH therapy, driven by repeat patients and predictable demand.
Streamlined distribution and limited promotional needs keep margins stable in a low-growth category, making it a dependable cash generator for the group.
NovoSeven — haemostasis
NovoSeven — haemostasis remains an entrenched, specialist hospital therapy with strong clinician trust following FDA approval in 1999; switching is cautious so volumes are steady and growth is low but predictable.
Operational efficiency and supply-chain focus outweigh broad marketing spend, making NovoSeven a reliable, high-margin contributor to Novo Nordisk’s specialty portfolio year after year.
- Product: NovoSeven (recombinant activated factor VII)
- Regulatory milestone: FDA approval 1999
- Market dynamics: specialist hospital use, low churn
- Commercial focus: operations > mass marketing
Saxenda (liraglutide 3mg) — obesity legacy
Saxenda (liraglutide 3mg) remains a cash cow in 2024 as legacy obesity revenue persists in markets where GLP‑1 uptake is slower versus semaglutide, though global demand has shifted markedly toward sema. Investments are light because manufacturing and sales infrastructure are already in place. Focus on optimizing pricing, tending existing accounts, and harvesting while promotional resources are redirected to sema.
- tag: legacy revenue — sustained in slower‑uptake markets (2024)
- tag: low capex — infrastructure established
- tag: pricing focus — optimize margins
- tag: promo shift — redirect spend to semaglutide
Harvest mature franchises; reallocate promo & capex to semaglutide growth
Insulin analogs, Victoza, Norditropin, NovoSeven and Saxenda are mature, high-share franchises in 2024 generating steady, high-margin cash flows with low growth and limited incremental investment; prioritize harvest, optimize mix and reallocate promo/capex to semaglutide opportunities.
| Product | 2024 Sales DKKbn (range) | Growth % | Role |
|---|---|---|---|
| Insulin analogs | 20–40 | ≈0–3 | Core cash cow |
| Victoza | ~10–15 | −5–0 | Harvest |
| Norditropin | 1–3 | 0–2 | Stable specialty cash |
| NovoSeven | 1–2 | 0–1 | High-margin specialist |
| Saxenda | 2–4 | −5–5 | Legacy obesity cash |
What You See Is What You Get
Novo Nordisk BCG Matrix
The file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the finished, fully formatted document. It’s crafted for strategic clarity and market-backed insight, ready to download the moment you buy. Use it for presentations, planning, or client work without edits. Nothing in the preview is different from the delivered file.
Dogs
Human insulin vials/mixes (legacy)
Human insulin vials/mixes (legacy) sit in a low‑growth, commoditized segment with sustained price pressure from generics and tendering; market growth is mid to low single digits. Share is fragmented with limited differentiation, and Novo Nordisk’s overall diabetes franchise held roughly 50% of global insulin revenue in 2024, but legacy vial margins are thin. These products are necessary for access programs, yet capital return is low, so maintain minimal footprint and avoid heavy turnarounds.
Repaglinide/older orals (off‑patent)
Repaglinide and other off‑patent oral agents show steep generic erosion and no clinical advantage versus newer GLP‑1s, leaving demand muted; in 2024 these legacy orals accounted for under 1% of Novo Nordisk’s diabetes portfolio. Heavy promotion is unlikely to be cost‑effective and the line is cash‑neutral at best, a management attention sink at worst. Clear candidates for pruning or divestment.
GlucaGen HypoKit (legacy glucagon)
GlucaGen HypoKit occupies a niche emergency-use segment for severe hypoglycemia, representing under 5% of the broader diabetes acute-care market and generating roughly €50–100m in annual sales in 2024 with modest ~3% CAGR. Intense convenience competition from nasal and ready-to-use glucagon alternatives has capped uptake and margin expansion. Hard to justify large capex given limited upside; maintain minimal spend while keeping supply reliable for strategic coverage.
Discontinued/retired insulin SKUs (e.g., Levemir in select markets)
Discontinued/retired insulin SKUs like Levemir in select markets are operational drag with little strategic value where withdrawn; transition and regulatory costs often outweigh ongoing benefits, so an orderly wind‑down frees manufacturing, regulatory and commercial resources for growth categories.
- Orderly wind‑down
- Transition costs > benefits
- Redeploy resources to growth
Commodity pen needles/accessories
Commodity pen needles/accessories sit in a highly competitive, price-led segment with low differentiation; the global pen-needle market was about USD 1.1bn in 2024 with single-digit CAGR, so volume without margin adds little to Novo Nordisk’s profitability. Expensive turnarounds and capex to differentiate rarely stick in this low-margin category. Recommend keep operations lean or pursue partnerships/outsourcing rather than build scale in-house.
- Market size 2024: ~USD 1.1bn
- Growth: single-digit CAGR
- Strategy: lean operations or partner out
- Risk: low margins, price-led competition
Prune low-growth insulin vials and orals; keep supply, partner on needles
Dogs are low‑growth, low‑share legacy insulin vials, off‑patent orals and accessories that tie up resources with thin margins; Novo Nordisk held roughly 50% of global insulin revenue in 2024 but legacy vial margins are weak. Legacy orals were <1% of the diabetes portfolio in 2024 and GlucaGen HypoKit made ~€50–100m. Strategy: minimal footprint, prune or divest, keep supply for access.
| Product | 2024 metric | Growth | Strategy |
|---|---|---|---|
| Legacy insulin vials | Within NN's 50% insulin rev (2024) | mid‑low SD | Maintain minimal footprint |
| Legacy orals | <1% portfolio | declining | Prune/divest |
| GlucaGen | €50–100m | ~3% CAGR | Maintain supply only |
| Pen needles | Market ≈USD1.1bn | single‑digit | Lean ops/partner |
Question Marks
CagriSema (cagrilintide + semaglutide) combo
CagriSema (cagrilintide + semaglutide) shows compelling efficacy signals but has zero commercial share today as it remains in development; global obesity drug TAM is projected to exceed USD 100 billion by 2030. Launch execution, payer access, and manufacturing/supply scale will determine uptake. Novo must commit heavy upfront investment in trials, launch and distribution; if it scales, it can become a Star rapidly.
Amycretin and next‑gen incretin pipeline
Amycretin and next‑gen incretin show high promise across weight and metabolic endpoints but remain early in the curve (Phase 1/2), needing robust clinical proof, scalable manufacturing plans and payer narratives. Development is cash hungry with uncertain timelines; benchmarking to tirzepatide's SURMOUNT‑1 22.5% mean weight loss highlights big upside if differentiation and phase‑3 data land.
Once‑weekly insulin icodec (new markets/labels)
Once-weekly insulin icodec, supported by the ONWARDS phase 3 program enrolling >6,000 patients, offers a 7-fold reduction in injection frequency and could materially reset the basal market if clinical outcomes and adherence translate to real-world benefits. Early uptake will likely be choppy as HCPs and payers revise protocols and formularies. Broad adoption requires targeted education, published outcomes and robust device integration. Novo must capture rapid share or face stalled momentum.
Cardio-renal indications for semaglutide expansion
Cardio-renal expansion targets large adjacent populations (diabetes ~537 million globally; CKD ~850 million affected), but Novo Nordisk’s semaglutide share in these indications remains nascent. Robust trial evidence shows cardiometabolic and renal benefit, yet label wins must convert to prescribing habits and reimbursement to drive uptake; targeted investment can tip standard of care.
- Large populations: T2D 537m; CKD ~850m
- Current share: nascent in cardio-renal
- Barrier: label→prescribing→reimbursement
- Evidence: strong but adoption needs push
- Recommendation: invest to tip SOC
Rare disease biologics pipeline (e.g., haemophilia innovations)
Rare disease biologics for haemophilia offer strong pricing power—eg Hemgenix launched at about 3.5 million USD—targeting small but growing niches; low initial share and complex, high-cost launches raise commercial and clinical risk. Scientific readouts and payer access milestones materially drive valuation; double down where clear differentiation exists and exit where it does not.
- High price: Hemgenix ~3.5M USD (launch)
- Small patient pools → high ASP, limited volume
- Milestones (efficacy, durability, reimbursement) = value inflection
Obesity TAM >USD100B by 2030; T2D 537M, CKD 850M — uptake hinges on phase‑3 & pricing
Question Marks: mid/late‑stage obesity/incretin assets (cagriSema, amycretins), once‑weekly insulin icodec, cardio‑renal and rare biologics show high upside but near‑zero commercial share; 2024 TAM signals: obesity >USD100B by 2030, T2D 537M, CKD ~850M, ONWARDS >6,000 patients; uptake hinges on phase‑3, pricing, reimbursement and manufacturing scale.
| Asset | Stage | 2024 signal | Key risk |
|---|---|---|---|
| cagriSema/amycretins | Phase2/3 | Obesity TAM >USD100B by 2030 | launch/payer access |
| icodec | Phase3 ONWARDS | >6,000 enrolled | real‑world adherence |
| cardio‑renal | early uptake | T2D 537M; CKD ~850M | label→reimbursement |
| haemophilia biologics | launch/early | ASP ~USD3.5M (Hemgenix) | payer access |